Ross Warshauer
Private Equity Analyst at 3i US
Profile
Ross Warshauer is currently working as an Associate at 3i US since 2021.
Prior to this, he worked as a Director at ten23 Health AG.
Mr. Warshauer completed his undergraduate degree from Goizueta Business School-Emory in 2019.
Ross Warshauer active positions
| Companies | Position | Start |
|---|---|---|
3i US
 3i US Investment ManagersFinance 3i U.S. is a venture capital firm headquartered in Menlo Park, California. The firm is a subsidiary of 3i Group Plc (LSE: III). | Private Equity Analyst | 2021-08-31 |
Former positions of Ross Warshauer
| Companies | Position | End |
|---|---|---|
ten23 Health AG
 ten23 Health AG BiotechnologyHealth Technology ten23 Health AG, founded in 2021, is a Swiss pharmaceutical company that specializes in designing, characterizing, and validating the manufacturing process for stability and preclinical purposes. The company is based in Basel, Switzerland, and has subsidiaries in Switzerland. The company is the partner of choice for the pharmaceutical industry and biotech start-ups for the development, manufacture, and testing of tomorrow ’ s medicines. The company's team of experts can test and evaluate the stability of a vast range of therapeutic modalities. | Director/Board Member | - |
Training of Ross Warshauer
| Goizueta Business School-Emory | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
3i US
3i US Investment ManagersFinance 3i U.S. is a venture capital firm headquartered in Menlo Park, California. The firm is a subsidiary of 3i Group Plc (LSE: III). | Finance |
ten23 Health AG
ten23 Health AG BiotechnologyHealth Technology ten23 Health AG, founded in 2021, is a Swiss pharmaceutical company that specializes in designing, characterizing, and validating the manufacturing process for stability and preclinical purposes. The company is based in Basel, Switzerland, and has subsidiaries in Switzerland. The company is the partner of choice for the pharmaceutical industry and biotech start-ups for the development, manufacture, and testing of tomorrow ’ s medicines. The company's team of experts can test and evaluate the stability of a vast range of therapeutic modalities. | Health Technology |
- Stock Market
- Insiders
- Ross Warshauer
